Navigation Links
Investigational New Drug Application for 'Fat Melting' Injections Cleared by the FDA
Date:9/4/2007

Clinical trial on injection lipolysis treatment to begin soon

NEW YORK, Sept. 4 /PRNewswire-USNewswire/ -- The Aesthetic Surgery Education and Research Foundation (ASERF) announced today that it has received approval from the U.S. Food and Drug Administration to initiate a clinical trial investigating the safety and efficacy of one type of injection lipolysis treatment.

Treatments most properly called injection lipolysis have been commonly associated with the terms mesotherapy or fat dissolving "Lipodissolve." These types of treatments claim to reduce or eliminate unwanted local accumulations of fat, but their ingredients and injection locations and techniques may vary slightly. There is also no standardized, consistent, and accepted injection protocol or chemical formulation, with many formulas being proprietary, and without scientifically valid studies documenting their safety or effectiveness or comparing one another. Injection lipolysis involves the injection of various compounds into the subcutaneous fat, but is not currently approved by the FDA for subcutaneous injection for any purpose.

"We are pleased to finally have the approval to move forward on this important clinical trial," said V. Leroy Young, MD, chief investigator for the study. "This study is long overdue, and will go a long way toward developing more standardized protocols and ultimately improving patient safety in this area."

The study, which was designed and funded by ASERF, will be conducted under FDA supervision and will follow patients for 46 weeks to evaluate the efficacy of one form of injection lipolysis and collect data on local and systemic reactions and any long-term complications. The study will include imaging, biochemical analysis and clinical measurements for objective evaluation of the efficacy and safety of the treatment.

"Although there are clinical reports of significant and positive results, they are all anecdotal, and unfortunately there is currently insufficient scientifically valid evidence to support the long term safety and efficacy of injection lipolysis. We hope that this study will provide the data needed to clarify some of the controversy and confusion surrounding this potentially beneficial treatment. The more we know, the better we will be able to educate and inform our patients, and recommend to them, with confidence, the safest and most effective treatments to provide them with the best results," said Alan H. Gold, MD, president of ASERF.

According to the American Society for Aesthetic Plastic Surgery's 2006 Cosmetic Surgery Statistics, injection lipolysis procedures were performed last year on 28,901 Americans -- six times the number of procedures performed the previous year.

About ASERF

The Aesthetic Surgery Education and Research Foundation (ASERF) is dedicated to directed research and physician education in cosmetic plastic surgery. ASERF helps to ensure the safety and effectiveness of new aesthetic (cosmetic) plastic surgical techniques and technologies by funding scientific research and clinical studies, and helps to make new treatments with proven benefits more widely available to patients who seek to improve their quality of life through aesthetic surgery. ASERF is a charitable organization, the research arm of the Society, 100% of member donations go to clinical research. http://www.aserf.org

About ASAPS

The American Society for Aesthetic Plastic Surgery, the leading organization of board-certified plastic surgeons specializing in cosmetic plastic surgery. ASAPS active-member plastic surgeons are certified by the American Board of Plastic Surgery or the Royal College of Physicians and Surgeons of Canada. http://www.surgery.org


'/>"/>
SOURCE Aesthetic Surgery Education and Research Foundation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New Drug Application Submitted for Investigational Antibiotic Doripenem
2. Astrazenecas Investigational Cancer Therapies Revealed at ASCO
3. Investigational Drug Being Pursued for the Treatment of Ischaemic Stroke
4. Novel Investigational Drug May Help American Women Suffering from Breast Pain
5. Novartis files application with FDA for Zometa
6. Morepan to file new drug applications with the USFDA
7. Mini motor for micromedical applications
8. Perfusion bioreactor could enhance stem cell research and application in the future
9. Prostate Cancer Can Be Treated By Application Of LASER Technology
10. Varied Applications of Adult Stem Cells to Treat Host of Disorders in Human
11. Venus Remedies Files 5th International Patent Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... ChenMed, a privately ... completion of the strategic executive team expansion needed to further optimize growth and ... executive team,” says Christopher Chen, MD, ChenMed Chief Executive Officer. “George Wheeler ...
(Date:3/23/2017)... ... March 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, ... build on a solid foundation. As experts in dangerous situations the Inflow IQ ... coming soon. Inflownomics deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Force Dagger Foundation the US Special Operations Command’s Patriot Award. The award was ... Thomas thanked Task Force Dagger Foundation for its significant and enduring support to ...
(Date:3/23/2017)... ... 23, 2017 , ... “Beyond and Back”: a true-life testimony of tragedy and ... published author Bonetta Rose, a wife, mother and grandmother committed to sharing her many ... Publishing, Bonetta Rose‘s new book presents actual events in the life of her family, ...
(Date:3/23/2017)... ... March 23, 2017 , ... “The Trainer”: an ... published author, Scotty, a fiction writer with an active imagination and an enthusiasm for ... book follows the tale of Wild Bill Hart, who sat looking at the thirty-three ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 2017 Ascendis Pharma A/S (Nasdaq: ASND), a ... address significant unmet medical needs in rare diseases, today ... and webcast on Monday, April 3 during ENDO 2017, ... Orlando, Florida , to discuss new data ... Hormone, TransCon PTH and TransCon CNP). Ascendis ...
(Date:3/23/2017)... - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") ... that AB Laboratories Inc. ("AB Labs") has successfully completed ... the Access to Cannabis for Medical Purposes Regulations ("ACMPR") ... The facility, which was licensed for Cultivation ... at half capacity, with full production capacity scheduled by ...
Breaking Medicine Technology: